Samsung Biologics

Incheon, South Korea, Rockville, Maryland, USA
Find alternatives to Samsung Biologics for Monoclonal Antibody →
Claimed Profile Monoclonal Antibody Recombinant Protein ADC mRNA Bispecific Antibody Antibody Conjugate
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
61.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (20) ○ EMA GMP ○ MHRA GMP

Quick Facts: Samsung Biologics

Signal Score
61.5/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
Incheon, South Korea, Rockville, Maryland, USA
Website
Modalities
Monoclonal Antibody, Recombinant Protein, ADC, mRNA, Bispecific Antibody, Antibody Conjugate
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Samsung Biologics

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesMonoclonal Antibody, Recombinant Protein, ADC, mRNA, Bispecific Antibody, Antibody Conjugate
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 63.0
Broad modality coverage (6 modalities)
Sites: Incheon, KR
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
StatusAvailable
Broad modality coverage (6 modalities)
Sites: Incheon, KR
Press Signals20 articles (not scored)
Broad modality coverage (6 modalities)

Hiring Activity 12 open roles Beta

From public job postings on Samsung Biologics' careers board, as of Nov 20, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
12
open roles
6
in manufacturing, quality, PD/MSAT, engineering or regulatory (50%)
Trend from Nov 25, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 24, 2027.
Since Nov 19, 2026: 0 new postings, 4 taken down.
By function
Manufacturing & operations 1
Quality (QA / QC) 2
Engineering & facilities 3
Commercial, BD & client projects 2
Other (finance, HR, IT, other) 4
By site
Rockville
1 mfg/ops · 2 QA/QC · 3 eng. · 5 other
11
New Jersey Sales Office
· 1 other
1
Latest postings
XMLNAME, CMO, Project Manager Commercial, BD & client projects · Rockville
Utilities Technician Engineering & facilities · Rockville
Analytical Systems Specialist Quality (QA / QC) · Rockville
EHS Manager Other (finance, HR, IT, other) · Rockville
Human Resources Generalist Other (finance, HR, IT, other) · Rockville
Process Maintenance Technician Engineering & facilities · Rockville
Facilities Maintenance Technician Engineering & facilities · Rockville
Sustainability Manager Other (finance, HR, IT, other) · Rockville
Sr Materials Planner Manufacturing & operations · Rockville
Site Electrician Other (finance, HR, IT, other) · Rockville
Business Development, Organoid Solutions, North America, Europe Commercial, BD & client projects · New Jersey Sales Office
Associate QC Chemist Quality (QA / QC) · Rockville
Coverage: counted from Samsung Biologics' own careers board. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: sba.wd102.myworkdayjobs.com · Checked Nov 20, 2026 · Tracking since Oct 26, 2026

Company Signals 20 articles

Company announcements, not verified evidence. They do not change any score.
general 2026-10-28
Samsung C&T commits $687M to Samsung Biologics' $2B rights offering - Dealroom
Samsung C&T commits $687M to Samsung Biologics' $2B rights offering  Dealroom
general 2026-10-28
Samsung Biologics: "Bispecific Antibody Development Time Cut by 3.5 Months" - 아시아경제
Samsung Biologics: "Bispecific Antibody Development Time Cut by 3.5 Months"  아시아경제
financial 2026-10-27
Samsung Biologics, Celltrion Hit Record Q3 Results, Intensifying Revenue Race - Businesskorea
Samsung Biologics, Celltrion Hit Record Q3 Results, Intensifying Revenue Race  Businesskorea
financial 2026-10-26
Samsung Biologics Revenue Up 18%, Profit Flat…Profitability Warning - 산경투데이
Samsung Biologics Revenue Up 18%, Profit Flat…Profitability Warning  산경투데이
regulatory 2026-10-24
Samsung Biologics wins court injunction covering all nine manufacturing stages - Indian Pharma Post
Samsung Biologics wins court injunction covering all nine manufacturing stages  Indian Pharma Post
general 2026-10-23
COINS Act, Hengrui, Samsung Biologics—Fierce Pharma Asia - Fierce Pharma
COINS Act, Hengrui, Samsung Biologics—Fierce Pharma Asia  Fierce Pharma
facility_expansion 2026-10-22
Samsung Biologics Reports KRW 1.49 Trillion Q3 Revenue as Global Manufacturing Expansion Drives Growth - BioPharma APAC
Samsung Biologics Reports KRW 1.49 Trillion Q3 Revenue as Global Manufacturing Expansion Drives Growth  BioPharma APAC
general 2026-10-22
Samsung Biologics' Q3 sales grow 19%, operating profit inches up - Korea Biomedical Review
Samsung Biologics' Q3 sales grow 19%, operating profit inches up  Korea Biomedical Review
financial 2026-10-22
Samsung Biologics raises 2026 growth outlook as quarterly revenue reaches KRW 1.49 trillion - BioSpectrum Asia
Samsung Biologics raises 2026 growth outlook as quarterly revenue reaches KRW 1.49 trillion  BioSpectrum Asia
general 2026-10-22
Samsung Biologics Hit Record Q3 Sales On Full Plant Utilization - Finimize
Samsung Biologics Hit Record Q3 Sales On Full Plant Utilization  Finimize
general 2026-10-21
Samsung Biologics Posts Record CDMO Sales of 1.49 Trillion Won - 조선일보
Samsung Biologics Posts Record CDMO Sales of 1.49 Trillion Won  조선일보
general 2026-10-20
Samsung Biologics wins strike ban across nine core bioprocess stages - Manufacturing Chemist
Samsung Biologics wins strike ban across nine core bioprocess stages  Manufacturing Chemist
general 2026-10-19
Sth Korean court backs Samsung Biologics’ manufacturing processes - The Pharma Letter
Sth Korean court backs Samsung Biologics’ manufacturing processes  The Pharma Letter
facility_expansion 2026-10-19
Samsung Biologics outlines ADC expansion plans at San Diego conference - Korea Biomedical Review
Samsung Biologics outlines ADC expansion plans at San Diego conference  Korea Biomedical Review
general 2026-10-19
Samsung Biologics Highlights ADC Manufacturing Strength - Businesskorea
Samsung Biologics Highlights ADC Manufacturing Strength  Businesskorea
general 2026-10-16
Court Halts Samsung Biologics Union Strike Over Key Processes - 조선일보
Court Halts Samsung Biologics Union Strike Over Key Processes  조선일보
general 2026-10-13
Samsung Biologics clears takeover threshold as 87.88% of PolyPeptide shares tendered - Korea Biomedical Review
Samsung Biologics clears takeover threshold as 87.88% of PolyPeptide shares tendered  Korea Biomedical Review
general 2026-10-07
Samsung Biologics pitches end-to-end CDMO services as Japan demand surges - Korea Biomedical Review
Samsung Biologics pitches end-to-end CDMO services as Japan demand surges  Korea Biomedical Review
general 2026-10-07
Samsung Biologics targets APAC market with end-to-end CDMO push - 헤럴드경제
Samsung Biologics targets APAC market with end-to-end CDMO push  헤럴드경제
general 2026-10-07
Samsung Biologics Speeds Japan, APAC End-to-End CDMO Push - 동아비즈니스리뷰
Samsung Biologics Speeds Japan, APAC End-to-End CDMO Push  동아비즈니스리뷰

Frequently Asked Questions About Samsung Biologics

What is Samsung Biologics's CDMO Signal Score?
Samsung Biologics has a Signal Score of 62/100, based on quality, operations, financial stability, and capacity data.
Evaluating Samsung Biologics for a manufacturing program?
Use the free AI matchmaker to compare Samsung Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Recombinant Protein CDMOs → ADC CDMOs → mRNA CDMOs → Antibody Conjugate CDMOs →

Similar CDMOs

Catalent
Tampa, FL
Signal Score: 76.1
Monoclonal Antibody, Recombinant Protein, ADC, AAV, mRNA, Plasmid DNA, Fill-Finish
Lonza
Basel, Switzerland
Signal Score: 72.8
AAV, Lentiviral, Cell Therapy, mRNA, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation, Small Molecule API, High-Potency APIs, Oral Solid Dose
AGC Biologics
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Signal Score: 79.9
CAR-T, Cell Therapy, AAV, Lentiviral, ADC, Monoclonal Antibody, Recombinant Protein, Microbial Fermentation
FUJIFILM Diosynth Biotechnologies
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Signal Score: 86.7
AAV, mRNA/LNP, Biologics, mRNA, Microbial Fermentation, Recombinant Protein
KBI Biopharma
Durham, NC · Boulder, CO
Signal Score: 84.1
Monoclonal Antibody, Recombinant Protein, AAV (analytical only), Plasmid DNA

Compare Samsung Biologics with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Samsung Biologics
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.